Hongjiang He

Dr. Hongjiang He


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2022 in Frontiers in Molecular Biosciences
Verified
Journal Article
Open access
TLTing Li
Ting Li
JLJuan Li
Juan Li
HWHaitao Wang
Haitao Wang
JZJiayu Zhao
Jiayu Zhao
MYMingze Yan
Mingze Yan
SYShan Yu
Shan Yu
Head and neck squamous cell carcinoma (HNSCC), originating from the mucosal epithelial cells of the oral cavity, pharynx, and larynx, is a lethal malignancy of the head and neck. Patients with advanced and recurrent HNSCC have poor outcomes due to limited therapeutic options. Exosomes have active roles in the pathophysiology of tumors and are suggested as a potential therapeutic target of HNSCC. Exosomes in HNSCC have been intensively studied for disease activity, tumor staging, immunosuppression, and therapeutic monitoring. In this review, the biological mechanisms and the recent clinical application of exosomes are highlighted to reveal the potential of exosomes as biomarkers and therapeutic targets for HNSCC.

10 September 2020 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
JZjiayu Zhao
jiayu Zhao
DLDaming Liu
Daming Liu
HYHao Yang
Hao Yang
SYShan Yu
Shan Yu
HHHongjiang He
Hongjiang He

21 August 2024 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
SDShuyan Dong
Shuyan Dong
MZMing Zhao
Ming Zhao
JZJin Zhu
Jin Zhu
TLTing Li
Ting Li
MYMingze Yan
Mingze Yan
HHHongjiang He
Hongjiang He
The interplay between immune components and the epithelium plays a crucial role in the development and progression of head and neck squamous cell carcinoma (HNSCC). Natural killer (NK) cells, one of the main tumor-killing immune cell populations, have received increasing attention in HNSCC immunotherapy. In this review, we explore the mechanism underlying the interplay between NK cells and HNSCC. A series of immune evasion strategies utilized by cancer cells restrict HNSCC infiltration of NK cells. Overcoming these limitations can fully exploit the antineoplastic potential of NK cells. We also investigated the tumor-killing efficacy of NK cell-based immunotherapies, immunotherapeutic strategies, and new results from clinical trials. Notably, cetuximab, the most essential component of NK cell-based immunotherapy, inhibits the epidermal growth factor receptor (EGFR) signaling pathway and activates the immune system in conjunction with NK cells, inducing innate effector functions and improving patient prognosis. In addition, we compiled information on other areas for the improvement of patient prognosis using anti-EGFR receptor-based monoclonal antibody drugs and the underlying mechanisms and prognoses of new immunotherapeutic strategies for the treatment of HNSCC.

21 February 2023 in International Journal of Oncology
Verified
Journal Article
Open access
PDF file
YHYuanyuan Hao
Yuanyuan Hao
TSTao Song
Tao Song
MWMingye Wang
Mingye Wang
TLTongtong Li
Tongtong Li
CZChi Zhao
Chi Zhao
HHHongjiang He
Hongjiang He
Cardiac glycosides (CGs) are candidate anticancer agents that function by increasing [Ca2+]i to induce apoptotic cell death in several types of cancer cells. However, new findings have shown that the anti‑cancer effects of CGs involve complex cell‑signal transduction mechanisms. Hence, exploring the potential mechanisms of action of CGs may provide insight into their anti‑cancer effects and thus aid in the selection of the appropriate CG. Periplocymarin (PPM), which is a cardiac glycoside, is an active ingredient extracted from Cortex periplocae. The role of PPM was evaluated in HepG2 cells and xenografted nude mice. Cell proliferation, real‑time ATP rate assays, western blotting, cell apoptosis assays, short interfering RNA transfection, the patch clamp technique, electron microscopy, JC‑1 staining, immunofluorescence staining and autophagic flux assays were performed to evaluate the function and regulatory mechanisms of PPM in vitro. The in vivo activity of the PPM was assessed using a mouse xenograft model. The present study demonstrated that PPM synchronously activated lethal apoptosis and protective autophagy in liver cancer, and the initiation of autophagy counteracted the inherent pro‑apoptotic capacity and impaired the anti‑cancer effects. Specifically, PPM exerted a pro‑­apoptotic effect in HepG2 cells and activated macroautophagy by initiation of the AMPK/ULK1 and mTOR signaling pathways. Activation of macroautophagy counteracted the pro‑apoptotic effects of PPM, but when it was combined with an autophagy inhibitor, the anti‑cancer effects of PPM in mice bearing HepG2 xenografts were observed. Collectively, these results indicated that a self‑limiting effect impaired the pro‑apoptotic effects of PPM in liver cancer, but when combined with an autophagy inhibitor, it may serve as a novel therapeutic option for the management of liver cancer.

3 November 2022 in Frontiers in Molecular Biosciences
Verified
Journal Article
Open access
TLTing Li
Ting Li
JLJuan Li
Juan Li
HWHaitao Wang
Haitao Wang
JZJiayu Zhao
Jiayu Zhao
MYMingze Yan
Mingze Yan
SYShan Yu
Shan Yu
Corrigendum: Exosomes: Potential biomarkers and functions in head and neck squamous cell carcinoma

8 September 2025 in Oncologie
Verified
Journal Article
Open access
PDF file
KXKaixun Xing
Kaixun Xing
XLXiaoqing Li
Xiaoqing Li
PLPeng Liu
Peng Liu
YGYinghao Guo
Yinghao Guo
HTHetai Teng
Hetai Teng
HHHongjiang He
Hongjiang He
Non-small cell lung cancer (NSCLC), which accounts for 85 % of all lung cancers, has been the focal point of cancer research for years and is associated with a high morbidity and mortality worldwide. Minimal residual disease (MRD) and expansion of drug-resistant clones after treatment are the main causes of recurrence in patients with NSCLC. These residual low-level diseases, coupled with mechanisms such as primary drug resistance, immune escape, bypass activation, and tissue-type transformation, have led to difficulties in anticancer therapy over the past decades. Recently, liquid biopsy has emerged as a powerful tool for early cancer detection and monitoring of treatment outcomes. Studies have demonstrated its potential in adjuvant cancer therapy and highlighted its advantages of low risk, high sensitivity, and other merits over other technologies. In this review, we assessed the detection samples and methods used in this technology and discussed the methods for detecting MRD and the latest progress in liquid biopsy for dynamically assessing the response of NSCLC to anticancer drugs, focusing on the application of liquid biopsies in NSCLC. Finally, we provide insights into future directions of liquid biopsies. We found that this technology enables the detection of undetectable MRD, assesses the efficacy of anticancer treatments, and ultimately reduces NSCLC recurrence, highlighting its potential therapeutic application.